Search for other papers by Roxanne C S van Adrichem in
Google Scholar
PubMed
Search for other papers by Aart Jan van der Lely in
Google Scholar
PubMed
Search for other papers by Martin Huisman in
Google Scholar
PubMed
Search for other papers by Piet Kramer in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
Search for other papers by Patric J D Delhanty in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
patients were reported to be positively correlated with tumor burden ( 29 ), total plasma ghrelin seems not to be a useful biomarker since total plasma ghrelin levels did not discriminate between patients with NETs and healthy controls ( 23 ). Currently
Search for other papers by V G Pluimakers in
Google Scholar
PubMed
Search for other papers by M van Waas in
Google Scholar
PubMed
Search for other papers by C W N Looman in
Google Scholar
PubMed
Search for other papers by M P de Maat in
Google Scholar
PubMed
Search for other papers by R de Jonge in
Google Scholar
PubMed
Search for other papers by P Delhanty in
Google Scholar
PubMed
Search for other papers by M Huisman in
Google Scholar
PubMed
Search for other papers by F U S Mattace-Raso in
Google Scholar
PubMed
Search for other papers by M M van den Heuvel-Eibrink in
Google Scholar
PubMed
Section Endocrinology, Department of Medicine, Erasmus MC, Rotterdam, The Netherlands
Search for other papers by S J C M M Neggers in
Google Scholar
PubMed
addition to the serum biomarkers triglycerides and HDL cholesterol that are already included in the definition of MetS, several other biomarkers have been suggested as surrogate markers for development of MetS and cardiovascular disease. These additional
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
Search for other papers by Eric Krenning in
Google Scholar
PubMed
Search for other papers by Anders Sundin in
Google Scholar
PubMed
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
Search for other papers by Margot Tesselaar in
Google Scholar
PubMed
Search for other papers by Valentina Ambrosini in
Google Scholar
PubMed
Search for other papers by Richard P Baum in
Google Scholar
PubMed
Search for other papers by Matthew Kulke in
Google Scholar
PubMed
Search for other papers by Marianne Pavel in
Google Scholar
PubMed
Search for other papers by Jaroslaw Cwikla in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Massimo Falconi in
Google Scholar
PubMed
Search for other papers by Nicola Fazio in
Google Scholar
PubMed
Search for other papers by Andrea Frilling in
Google Scholar
PubMed
Search for other papers by Robert Jensen in
Google Scholar
PubMed
Search for other papers by Klaus Koopmans in
Google Scholar
PubMed
Search for other papers by Tiny Korse in
Google Scholar
PubMed
Search for other papers by Dik Kwekkeboom in
Google Scholar
PubMed
Search for other papers by Helmut Maecke in
Google Scholar
PubMed
Search for other papers by Giovanni Paganelli in
Google Scholar
PubMed
Search for other papers by Ramon Salazar in
Google Scholar
PubMed
Search for other papers by Stefano Severi in
Google Scholar
PubMed
Search for other papers by Jonathan Strosberg in
Google Scholar
PubMed
Search for other papers by Vikas Prasad in
Google Scholar
PubMed
Search for other papers by Aldo Scarpa in
Google Scholar
PubMed
Search for other papers by Ashley Grossman in
Google Scholar
PubMed
Search for other papers by Annemeik Walenkamp in
Google Scholar
PubMed
Search for other papers by Mauro Cives in
Google Scholar
PubMed
Search for other papers by Irene Virgolini in
Google Scholar
PubMed
Search for other papers by Andreas Kjaer in
Google Scholar
PubMed
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
assessment by imaging, biomarker levels and overall survival represents the fundamental basis for all management strategies. The need to monitor tumor responsiveness, both in clinical trials and in routine practice, is mandatory given the range of expensive
Search for other papers by Hyunjae Lee in
Google Scholar
PubMed
Search for other papers by Tae-Shin Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Ja-Yoon Gu in
Google Scholar
PubMed
Search for other papers by Mi Ran Yu in
Google Scholar
PubMed
Search for other papers by Seung-Eun Lee in
Google Scholar
PubMed
Search for other papers by Eun Sook Kim in
Google Scholar
PubMed
Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Search for other papers by Hyun Kyung Kim in
Google Scholar
PubMed
to identify various biomarkers for detecting recurrence of DTC ( 3 ), however, serum thyroglobulin is still primarily used for follow-up of patients with DTC, particularly after total thyroidectomy and radioactive iodine ablation ( 4 ). In DTC
Nanchang University, Nanchang, Jiangxi Province, China
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Shikai Gui in
Google Scholar
PubMed
Nanchang University, Nanchang, Jiangxi Province, China
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Wanli Yu in
Google Scholar
PubMed
Nanchang University, Nanchang, Jiangxi Province, China
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Jiabao Xie in
Google Scholar
PubMed
Nanchang University, Nanchang, Jiangxi Province, China
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Lunshan Peng in
Google Scholar
PubMed
Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Yuanyuan Xiong in
Google Scholar
PubMed
Department of Urology, the 2nd affiliated hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Zhen Song in
Google Scholar
PubMed
Search for other papers by Haitao Luo in
Google Scholar
PubMed
Search for other papers by Juexian Xiao in
Google Scholar
PubMed
Search for other papers by Shengtao Yuan in
Google Scholar
PubMed
Nanchang University, Nanchang, Jiangxi Province, China
Institute of Neuroscience, Nanchang University, Nanchang, Jiangxi Province, China
Search for other papers by Zujue Cheng in
Google Scholar
PubMed
found that SLC7A11 functions as an invasive biomarker and was highly expressed in invasive PitNETs. In addition, knockdown of SLC7A11 inhibited epithelial–mesenchymal transition (EMT) through the PI3K/AKT signaling pathway. Materials and methods
Search for other papers by Vito Francic in
Google Scholar
PubMed
Search for other papers by Martin Keppel in
Google Scholar
PubMed
Search for other papers by Verena Schwetz in
Google Scholar
PubMed
Search for other papers by Christian Trummer in
Google Scholar
PubMed
Search for other papers by Marlene Pandis in
Google Scholar
PubMed
Search for other papers by Valentin Borzan in
Google Scholar
PubMed
Search for other papers by Martin R Grübler in
Google Scholar
PubMed
Search for other papers by Nicolas D Verheyen in
Google Scholar
PubMed
Search for other papers by Marcus E Kleber in
Google Scholar
PubMed
Search for other papers by Graciela Delgado in
Google Scholar
PubMed
Search for other papers by Angela P Moissl in
Google Scholar
PubMed
Search for other papers by Benjamin Dieplinger in
Google Scholar
PubMed
Synlab Academy, Synlab Holding Germany GmbH, Heidelberg, Germany
Search for other papers by Winfried März in
Google Scholar
PubMed
Search for other papers by Andreas Tomaschitz in
Google Scholar
PubMed
Search for other papers by Stefan Pilz in
Google Scholar
PubMed
Search for other papers by Barbara Obermayer-Pietsch in
Google Scholar
PubMed
as their biomarker surrogates but also the seasonal prevalence of vitamin D deficiency ( 1 , 2 , 3 ). Soluble ST2 (sST2) is the truncated, soluble form of the ST2 receptor found in the circulation and functions as a decoy receptor, binding IL-33
Search for other papers by Anna Malczewska in
Google Scholar
PubMed
Search for other papers by Magdalena Witkowska in
Google Scholar
PubMed
Search for other papers by Karolina Makulik in
Google Scholar
PubMed
Search for other papers by Agnes Bocian in
Google Scholar
PubMed
Search for other papers by Agata Walter in
Google Scholar
PubMed
Search for other papers by Joanna Pilch-Kowalczyk in
Google Scholar
PubMed
Search for other papers by Wojciech Zajęcki in
Google Scholar
PubMed
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
Search for other papers by Beata Kos-Kudła in
Google Scholar
PubMed
PNETs without liver involvement, carcinoid syndrome occurs very rarely ( 2 ). Circulating indicators of tumor secretory functionality (amines or peptides) hence represent a minority of NETs. Measurement of secretory biomarkers is therefore de facto
Search for other papers by Anna Malczewska in
Google Scholar
PubMed
Search for other papers by Kjell Oberg in
Google Scholar
PubMed
Search for other papers by Beata Kos-Kudla in
Google Scholar
PubMed
Introduction Neuroendocrine neoplasms (NENs) constitute a heterogeneous group of neoplasia whose diagnosis is established by symptomology, biomarkers, multimodal imaging and histopathology ( 1 ). Diagnosis is difficult since symptomatology is
MRC Epidemiology Unit, Department of Epidemiology and Department of Internal Medicine, University of Cambridge School of Clinical Medicine, Institute of Metabolic Science, Cambridge Biomedical Campus, Addenbrooke's Hospital, Post Box 285, Cambridge CB2 0QQ, UK
Search for other papers by Ali Abbasi in
Google Scholar
PubMed
Introduction Over the past decade, interest in studying biological markers (biomarkers) for type 2 diabetes (T2D) has increased intensely. This happened because multiple pathobiological processes may contribute to the disease progression, which
Search for other papers by Irvin M Modlin in
Google Scholar
PubMed
Search for other papers by Harry Aslanian in
Google Scholar
PubMed
Wren Laboratories, Yale University School of Medicine, 35 NE Industrial Road, Branford, Connecticut, USA
Search for other papers by Lisa Bodei in
Google Scholar
PubMed
Search for other papers by Ignat Drozdov in
Google Scholar
PubMed
Search for other papers by Mark Kidd in
Google Scholar
PubMed
biomarkers (1) . An accurate tumor marker is a critical tool in tumor management, because it establishes an uncertain diagnosis, offers a basis for individual prognostication, signals response to therapy, and identifies relapse. In classical terms, a high